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Abstract: There is a need to identify the regulatory gene interaction of anticancer drugs on 
target cancer cells. Whole genome expression proﬁ  ling offers promise in this regard, but can 
be complicated by the challenge of identifying the genes affected by hundreds to thousands of 
genes that induce changes in expression. A proteasome inhibitor, bortezomib, could be a potential 
therapeutic agent in treating adult T-cell leukemia (ATL) patients, however, the underlying 
mechanism by which bortezomib induces cell death in ATL cells via gene regulatory network 
has not been fully elucidated. Here we show that a Bayesian statistical framework by VoyaGene® 
identiﬁ  ed a secreted protein acidic and rich in cysteine (SPARC) gene, a tumor-invasiveness 
related gene, as a possible modulator of bortezomib-induced cell death in ATL cells. Functional 
analysis using RNAi experiments revealed that inhibition of the expression SPARC by siRNA 
enhanced the apoptotic effect of bortezomib on ATL cells in accordance with an increase of 
cleaved caspase 3. Targeting SPARC may help to treat ATL patients in combination with 
bortezomib. This work shows that a network biology approach can be used advantageously to 
identify the genetic interaction related to anticancer effects.
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Introduction
Gene expression microarrays yield quantitative and semiquantitative data on the cell 
status in a speciﬁ  c condition and time. The aim is to infer, or ‘reverse-engineer’, from 
gene expression data, the regulatory interactions among genes using computational 
algorithms. The interaction between two genes in a gene network does not necessarily 
imply a physical interaction, but can also refer to an indirect regulation via proteins, 
metabolites and noncoding RNA that have not been measured directly. In practical 
terms, however, the meaning of interactions is not well deﬁ  ned and depends on 
mathematical formations used to model networks (Bansal et al 2007). In this study, 
we show that a network biology approach can be used for this. In particular, we show 
that reverse-engineered gene networks can be combined with expression proﬁ  les to 
identify the genes which may play an important role in genetic networks. We used a 
Bayesian network using a computational tool, VoyaGene® (Mitsui Knowledge Industry, 
Tokyo, Japan), which has been validated as a means to identify the genes related to 
viral infection (Takaku et al 2005).
Adult T-cell leukemia/lymphoma (ATL), an aggressive malignancy of CD4+ 
lymphocytes, is caused by the retrovirus HTLV-1 (Matsuoka and Jeang 2005). 
ATL is resistant to chemotherapy and has a very poor prognosis, which underlines 
the need for new and effective therapeutic approaches. The proteasome inhibitor, Advances and Applications in Bioinformatics and Chemistry 2008:1 86
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bortezomib (also known as Velcade or PS-341), represents 
a new class of anticancer drugs which has been shown to 
inhibit the growth and/or progression of human cancers, 
including multiple myeloma (Mitsiades et al 2002; Cavo 
2006; Rajkumar et al 2006). Using DNA microarray 
analysis, we have recently shown that bortezomib-induced 
cell death via multiple pathways in ATL cell lines and 
induction of heme oxygenase-1 by cobalt protoporphyrin 
enhances the antitumour effect of bortezomib in adult 
T-cell leukemia cells (Hamamura et al 2007). Despite the 
fact that bortezomib affects several pathways critical for 
the survival of HTLV-1-positive and negative malignant 
T cell (Satou et al 2004; Nasr et al 2006), the gene 
regulatory network by which bortezomib inhibits ATL 
cell growth has not been fully elucidated. In addition, 
threshold-dominated analysis of DNA microarray analysis 
hides critical genes which may interfere with large 
numbers of genes.
The above points led us to hypothesize that a network 
biology approach might be able to indicate regulatory 
interactions among genes associated with the anticancer 
effect of bortezomib on ATL cells. We constructed a 
pathway-focused oligonucleotide array which contained a 
limited number of genes, and explored a gene network-based 
analysis, seeking to evaluate the molecular pathways which 
might be involved in the bortezomib-induced antiproliferative 
effect on ATL cells.
Materials and methods
Reagents and cells
Time-course experiments were done as follows; An ATL 
cell line, designated, TaY (Zhou 1998) was treated with 
0.5 to 100 nM of bortezomib for 8 h, 12 h, 24 h, 48 h, and 
72 h. The antiproliferative effect of bortezomib on TaY 
(IC50; 5 nM) has been reported elsewhere (Hamamura et al 
2007). Two interleukin-2 (IL-2) independent ATL cell lines 
(MT-2, and MT-4) and, after obtaining written informed 
consent, peripheral blood cells isolated from a patient with 
ATL were also used in a part of our study (Hamamura et al 
2007). Bortezomib was kindly provided by Millennium 
Pharmaceutials Inc., (Cambridge, MA, USA). The inhibitory 
effect of bortezomib on cell growth was assessed by a cell 
counting kit (Wako Chemicals, Tokyo, Japan). For detection 
of apoptosis, the Annexin V-binding capacities of the treated 
cells were examined by Annexin V-biotin apoptosis detec-
tion kit (Calbiochem, La Jolla, CA, USA) using an Agilent 
2100 Bioanalyzer (Agilent, MA, USA), according to the 
manufacturer’s instructions.
DNA microarray analysis, data validation, 
and statistics
A schematic diagram of our strategy to identify the gene 
network which may be involved with bortezomib-induced 
cell death in ATL cells is shown in Figure 1. We designed 
an in-house pathway-focused low-density oligonucleotide 
microarray (GPL 3837: Novusgene Inc., Tokyo, Japan) 
in order to perform repeated time course experiments and 
construct a gene network by the following Bayesian method. 
For dual color analysis, cDNA obtained from untreated cells 
was labeled with Cy3 as a reference, and cDNA obtained 
from the bortezomib-treated cells was labeled with Cy5. 
Hybridization was carried out automatically using GeneTAC 
Hybstation (Genomic Solutions, AnnArbor, MI, USA), as 
reported previously (Zhang et al 2006). The hybridization 
signals were scanned by GenePix 4000B (Axon Instruments, 
Union City, CA, USA). For statistical analysis of gene 
expression, we utilized a GeneSifter® (VizXLabs, Seattle, 
WA, USA). Analysis of variance (ANOVA), and Student’s 
t-test, were done using GeneSifter®. P-values of less than 
0.05 were considered to indicate a statistically signiﬁ  cant 
difference and the Benjamini-Hochberg algorithm was used 
for estimation of false discovery rates, as reported previously 
(Zhang et al 2006).
Genetic network analysis using 
a VoyaGene®
We next performed a gene network analysis employing 
a Bayesian network using the VoyaGene® to construct 
an artificial genetic network from the microarray gene 
expression data. The Bayesian network is a graph-based 
model that statistically investigates the characteristics of 
dependence and conditional independence between data 
sets of variables (Maki et al 2004). We exploited plausible 
network structures from the causal relationships with the 
statistically highest possibility between the variables. Since 
it is difﬁ  cult to investigate all network structure comprehen-
sively for large number of genes by conventional Bayesian 
networks, we established an original evaluation formula 
we named “score value” focusing on the binary relations 
included in the network structure. When we consider graphs 
over three nodes X1, X2 and X3, the total number of possible 
network structures is 25 (Figure 2). The detailed formula for 
the score value of each binary relations included in network 
structure, Sk (k = 1, 2,... , the number of binary relations) is 
shown in Supplementary File 1. The closer the value of Sk 
approaches 1.0, the greater the possibility that the binary relation 
k exists. In contrast, the closer the value of Sk approached Advances and Applications in Bioinformatics and Chemistry 2008:1 87
Gene regulatory network in bortezomib-treated ATL cells
1. In-house-made oligonucleotide 
array containing 667 genes 
(GPL3837)
2. Repeated time-series experiments
with various concentration of drug
3. Reverse-engineered gene network
(Bayesian method)
4. Knock-down of the candidate gene
 Biological relevance →  
Figure 1 A schematic diagram of gene expression analysis using a Bayesian method as applied to identify genetic interaction for anticancer effect of bortezomib in ATL cells.
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Figure 2 Estimated binary relations among 3 genes. When we consider permutations of three nodes X1, X2 and X3, the total number of the possible network structures is 25.
zero, the less likely the existence of the binary relation k. In 
the current study, we selected relations with score value was 
greater than 0.2 to validate the correlation of each gene.
Small interfering RNA (siRNA)
To conﬁ  rm the results obtained from the network-based anal-
ysis, RNAi experiments were done. siRNA oligonucleotides 
for the secreted protein acidic and rich in cysteine (SPARC) 
and β-actin (control) were purchased from Ambion (Austin, 
TX, USA) and resuspended in RNase-free-H2O as 20 μM 
solutions according to the manufacturer’s instructions. TaY 
cells were transfected with SPARC or control siRNA in the 
presence or absence of 5n M of bortezomib. For cell transfec-
tion, approximately 5 × 105 cells were plated in six-well plates Advances and Applications in Bioinformatics and Chemistry 2008:1 88
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to give 50% conﬂ  uency. The cells were transfected with a ﬁ  nal 
siRNA concentration of 30 nM using siPORT™ NeoFX™ 
Transfection Agent (Ambion). After 48 h, cell viability and 
apoptosis assays were done. Efﬁ  cacy of transfection was 
evaluated by Western blotting as well as real-time RT-PCR as 
reported elsewhere (Hamamura et al 2007). Primary antibodies 
used in the current study are anti-SPARC, anti-vascular 
endothelial growth factor-B (anti-VEGF-B), fibroblast 
growth factor-1 (FGF-1) (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), antiactin (Chemicon), and anti-GAPDH 
(Abcam Plc., Cambridge, UK).
Results
Gene network analysis 
by Bayesian statistical framework 
in bortezomib-treated TaY cells
Repeated time-series experiments were done using in-house 
oligonucleotide DNA microarray which contains a limited 
number of genes (NCBI Gene expression omnibus, GSE5794, 
released), since the Bayesian method requires abundant 
experimental data sets to obtain statistically significant 
results. To seek how each gene interfered with each other in 
bortezomib-induced cell death, we analyzed the relationship 
of 667 genes by the Bayesian statistical network analysis using 
VoyaGene®. We extracted several relations the score value of 
which was greater than 0.2, and the list of selected genes was 
attached as Supplementary File 2. Based on our evaluation 
system (Supplementary File 1), we extracted an artiﬁ  cial 
gene network involving 3 genes: SPARC, NLR family, pyrin 
domain containing 12 (NAPL12), ankyrin 1 (ANK1). Among 
them, we in particular focused a gene network involving 
SPARC (Figure 3). Artiﬁ  cial gene network involving NALP12 
and ANK1 are shown in Supplementary File 3.
Down-regulation of SPARC 
in bortezomib-treated ATL cells
To validate whether SPARC indeed reflect molecular 
pathways in bortezomib-treated ATL cells, we analyzed 
the gene expression levels of SPARC in bortezomib-treated 
ATL cell lines as well as ATL cells obtained from a patient. 
Positive correlation
ie,Gene A Gene  B
Negative correlation
ie,Gene A Gene  B
FGF1
VEGFB
SPARC
↑
↑
↑
↑
Figure 3 Artiﬁ  cial gene regulatory network integrated to SPARC conduced by VoyaGene®. Genes are analyzed by the Bayesian statistical network analysis. Nodes indicate genes 
and edges represent regulations between genes; red line (when gene A is up-regulated, gene B is up-regulated), blue line (when gene A is up-regulated, gene B is down-regulated).Advances and Applications in Bioinformatics and Chemistry 2008:1 89
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The SPARC expression level was elevated in bortezomib-treated 
fresh ATL cells as well as an ATL cell lines. This indicates 
that the molecular pathway involving SPARC may play 
some roles in de novo ATL cells treated with bortezomib 
(Figure 4).
Knock-down of SPARC enhance 
the bortezomib-induced cell death 
in TaY cells
To test the functional importance of SPARC in bortezomib-
induced cell death, we performed the RNAi experiment in the 
presence or absence of pharmacological dose of bortezomib. 
TaY cells were transfected with control siRNA (β-actin) 
or SPRC siRNA. The SPARC siRNA speciﬁ  cally reduced 
SPARC expression, while the β-actin siRNA did not affect 
the SPARC expression level (Figure 5A). The reduction 
of SPARC expression was more evident in cells treated 
with bortezomib and SPARC siRNA. The control siRNA 
showed modest reduction of β-actin expression at the pro-
tein level, however, real-time PCR revealed the reduction of 
β-actin mRNA (Figure 5B). We then collected cells at 48 h 
after transfection, to measure cell viability and apoptosis. 
Inhibition of SPARC gene expression by SPARC siRNA 
alone did not affect the cell viability, however, it enhanced the 
antiproliferative activity of bortezomib (p = 0.042) (Figure 5). 
In contrast, inhibition of control gene expression did not 
affect antiproliferative activity of bortezomib. The synergic 
effect of bortezomib and SPARC siRNA with respect to cell 
viability was relatively small possibly due to cytotoxicity of 
bortezomib, increasing apoptotic effect of SPARC siRNA 
was more evident in the presence of 5 nM of bortezomib 
(p = 0.011) (Figure 7).
Effect of SPARC RNAi on VEGF-B 
and FGF1 expression
To elucidate the possible correlation between genes involved 
in the artiﬁ  cial network, we next analyzed the effect of SPARC 
RNAi on VEGF-B and FGF-1. In the presence of bortezomib, 
inhibition of SPARC gene expression remarkably suppressed 
either VEGF-B or FGF-1 expression (Figure 8). This indi-
cates that positive correlations ﬁ  gured out by the Bayesian 
method make perfect sense in bortezomib-treated TaY cells. 
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Figure 4 Comparison of gene expression levels between cell lines and a patient sample. Percent of ATL cells in the peripheral blood specimens is 76% respectively. Relative 
gene expression levels are expressed as ratios (copy numbers of target gene / copy numbers of GAPDH). In the presence of bortezomib, and down-regulation of SPARC is 
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Figure 5 Effect of SPRC siRNA on TaY cells. Twenty four hours after transfection with SPARC or control siRNA, bortezomib is added to the culture. A: Western blot reveals 
that SPARC siRNA induce modest reduction of SPARC protein levels in TaY cells, while SPARC siRNA does not affect β-actin protein levels. SPARC expression is remarkably 
reduced when cells were treated with SPARC siRNA followed by bortezomib. B: Reduction of target gene by RNAi: relative gene expression levels are expressed as ratios 
(copy numbers of target gene/copy numbers of GAPDH).
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Figure 6 SPARC siRNA enhances bortezomib-induced cell death on TaY cells. Bortezomib induces antiproliferative effect in TaY cells (p = 1.33E-07). Inhibition of SPARC gene 
expression by SPARC siRNA also enhances the antiproliferative activity of bortezomib (p = 0.039).
In addition, SPRC RNAi directly affects the increase of 
cleaved caspase 3. This suggests that SPARC RNAi enhances 
apoptosis in the presence of bortezomib, accompanied with 
VEGF-B and FGF-1 inhibition.
Discussion
Construction of gene networks from microarray gene expression 
data is becoming an important area in the post-genome era 
(Zhou et al 2003; Hubner et al 2005). Gene network interference 
algorithms are becoming accurate enough to be of practical 
value. Recently, Ergun and colleagues (2007) have reported 
a network biology approach to prostate cancer utilizing the 
microarray data sets deposited in a public database. In this study, 
we performed wet-experiments using an in vitro model, and 
performed computational analysis using Bayesian algorithms 
from the aspects of a network biology approach. Although we Advances and Applications in Bioinformatics and Chemistry 2008:1 91
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Figure 7 SPARC siRNA enhances bortezomib-induced apoptosis in TaY cells. Apoptosis is expressed as a percent of Annexin V positive cells in bortezomib and or siRNA 
treated cells. SPARC siRNA induces apoptosis in the presence of 5 nM of bortezomib (p = 0.011).
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Figure 8 Inhibition of   VEGF-B and FGF-1 expression in bortezomib and siRNA treated TaY cells. In the presence of bortezomib, inhibition of SPARC gene expression remark-
ably suppresses either VEGF-B or FGF-1 expression. In contrast, SPARC siRNA enhanced the cleavage of caspase 3 in the presence of bortezomib, indicating that SPARC 
siRNA enhanced bortezomib-induced apoptosis in TaY cells.
could not perform network analysis using high-density DNA 
microarrays such as Afﬁ  metrix’s GeneChip, our time series data 
allowed us to investigate the dynamics of activation (inhibition) 
of genes in response to bortezomib treatment in ATL cells. 
Our ﬁ  nal goal was to assimilate cellular biological research 
(ie, wet-experiments) and bioinformatics, and we found that a 
reverse-engineered gene network can be used to identify the 
molecular target related to anticancer effect.Advances and Applications in Bioinformatics and Chemistry 2008:1 92
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SPARC/osteonectin/BM-40 is a matrix-cellular protein 
that is thought to play some roles in tumor progression (Hadvat 
et al 2003; Kato et al 2005; Rich et al 2005; Chlenski et al 
2006; Infante et al 2007; Lien et al 2007). We investigated 
the possibility of inferring the local network of regulatory 
interaction surrounding SPARC even when there is no a 
priori knowledge of genes belonging to the network. Recent 
microarray and immunohistochemical analysis of human 
cancer indicate a relatively high level of SPARC (Kato 
et al 2005; Lien et al 2007). These reports have suggested 
a correlation between the level of SPARC expression and 
clinical outcome (Rich et al 2005; Infante et al 2007). 
Conversely, a high level of SPARC was correlated with a 
better prognosis in neuroblastoma, possibly due to impaired 
angiogenesis (Chlenski et al 2006). Although the mechanism 
underlying the capacity of SPARC to promote or inhibit tumor 
progression in different tumor microenvironments remains 
under investigation, it may depend on the types of cancer, the 
source of SPARC, and the site of tumor growth.
Recent studies have demonstrated that SPARC is related 
to the VEGF functions, tumor angiogenesis, and extravasation 
of tumors mediated by the increased permeability of the 
endothelial barrier (Goldblum et al 1994; Kato et al 2001). 
A recent study demonstrated that ATL- and HTLV-I-
associated myelopathy patients exhibit high plasma levels 
of functional VEGF and basic FGF (Bazabachi et al 
2004). The interaction of HTLV-I-transformed cells with 
endothelial cells induces the gelatinase activity of matrix 
metalloproteinase (MMP)-2 and MMP-9 in endothelial cells 
and down-regulates the tissue inhibitor of MMP (Bazabachi 
et al 2004). This leads to subendothelial basement membrane 
degradation followed by endothelial cell retraction, allowing 
neoplastic lymphocyte extravasation. In the current study, we 
also found a positive correlation between SPARC and FGF-1. 
It is likely that SPARC acts at the crossroads of cell-matrix 
communication (Brekken and Sage 2001). Extra-nodal 
inﬁ  ltration of ATL cell such as skin and spleen is frequently 
seen and this invasive characteristic of ATL cells seems to be 
one factor affecting the poor prognosis in ATL (Yamada et al 
1997; Yagi et al 2003). Our results suggest that bortezomib 
has the potential to prevent ATL cell invasion by inhibiting 
SPARC. It should obviously be clariﬁ  ed in large numbers 
of patient specimen.
Conclusion
Our study clearly shows that the reverse-engineered analysis 
worked adequately and that the extracted gene, SPARC, 
may be involved in bortezomib-induced cell death in 
ATL cells. The integration of bioinformatics, system biology, 
and carefully designed models will provide more insight into 
the biological role of SPARC. Targeting SPARC may also 
be effective in treating ATL patients exhibiting extra-nodal 
lesions such as skin invasion. Applying network-based 
analysis in addition to gene expression proﬁ  ling may be 
a new option to obtain novel insights into the proteasome 
inhibitor, bortezomib, in not only ATL, but also various 
types of human cancer.
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Supplementary File 1
Formula for score value
We arbitrarily deﬁ  ne the possibility of each network struc-
ture to be P(Bi)(i = 1, 2, ….., 25). In the cases of three-gene 
networks, six kinds of binary relations can be considered; 
X1-X2, X1-X3, X2-X1, X2-X3, X3-X1, X3-X2. 
The score value of each binary relations included in network 
structure, Sk (k = 1, 2, ...; the number of binary relations), can 
be deﬁ  ned as follows:
  S
PB
PB
k
i
r
i
ii
=
− Σ
Σ
{( ) ( )}
{( ) }
1
 
(i = 1, 2, …; the number of possible network structures)
(for cases when the binary relation k is not included in 
the ith network structure, Bi, r = 1; for the case when 
binary relation k is included in the network structure, Bi, 
r = 2).
The score value of binary relation X1-X2 depicted in 
Figure, deﬁ  ned by S1, can be calculated as follows;
S1 = {P(B6) + P(B8) + P(B12) + P(B14) + P(B19) + P(B20) + 
P(B21) + P(B24)
– P(B1) – P(B2) – P(B3) – P(B4) – P(B5) – P(B7) – P(B9) 
– P(B10) – P(B11) – P(B13)
– P(B15) – P(B16) – P(B17) – P(B18) – P(B22) – P(B23) 
– P(B25)}/
∑i{P(Bi)} (i = 1, 2, ……, 25)
The closer the value of Sk approaches 1.0, the greater 
the possibility that the binary relation k exists. In contrast, 
the closer the value of Sk approached zero, the less likely the 
existence of the binary relation k.
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Genes Relation Network Score value
TCF7L2(NM_030756:TCF7L2)  1 A 0.2299
CCL27(NM_006664:CCL27)  1 A 0.2299
APOB(NM_000384:APOB)  1 A 0.2299
FGF1(NM_033136:FGF1)  1 A 0.2299
TCF1(NM_000545:TCF1)  1 A 0.2299
CXCL3(NM_002089:CXCL3)  1 A 0.2299
RAD1(NM_002853:RAD1)  1 A 0.2299
POU2AF1(NM_006235:POU2AF1)  1 A 0.2299
NCOA4(NM_005437:NCOA4) −1 A 0.2299
IL12A(NM_000882:IL12A)  1 A 0.2299
TNR(NM_003285:TNR)  1 A 0.2299
WNT2B(NM_004185:WNT2B)  1 A 0.2299
TCEAL1(NM_004780:TCEAL1)  1 A 0.2299
XRCC2(NM_005431:XRCC2)  1 A 0.2299
COL1A1(NM_000088:COL1A1)  1 A 0.2299
CASP5(NM_004347:CASP5)  1 A 0.2299
TFAP2C(NM_003222:TFAP2C)  1 A 0.2299
HTR2B(NM_000867:HTR2B)  1 A 0.2299
ABCA1(NM_005502:ABCA1)  1 A 0.2299
IL7(NM_000880:IL7) −1 A 0.2299
CXCL12(NM_000609:CXCL12)  1 A 0.2299
IL12RB1(NM_005535:IL12RB1)  1 A 0.2299
TRAF5(NM_004619:TRAF5)  1 A 0.2299
VEGFB(NM_003377:VEGFB)  1 A 0.2299
IGF2R(NM_000876:IGF2R)  1 A 0.2299
IL10RA(NM_001558:IL10RA) −1 A 0.2299
FGF10(NM_004465:FGF10)  1 A 0.2299
TCF4(NM_003199:TCF4)  1 A 0.2299
ILF3(NM_004516:ILF3)  1 A 0.2299
NASP(NM_002482:NASP)  1 A 0.2299
TNFRSF10A(NM_003844:TNFRSF10A)  1 A 0.2299
ALOX15(NM_001140:ALOX15)  1 A 0.2299
POU4F2(NM_004575:POU4F2)  1 A 0.2299
CTNND2(NM_001332:CTNND2)  1 A 0.2299
IL20RA(NM_014432:IL20RA)  1 A 0.2299
GJA3(NM_021954:GJA3)  1 A 0.2299
HUS1(NM_004507:HUS1)  1 A 0.2299
(Continued)
Supplementary File 2
List of genes with scores greater than 0.2 
selected by Voyagene® (Raw data)
Three networks (A to C) with scores greater than 0.2 was 
shown below.
Relation 1: positive correlation
Relation 1: negative correlation
A: an artiﬁ  cial gene network terminating and integrating 
into SPARC
B: an artiﬁ  cial gene network terminating and integrating 
into NALP12
C: an artiﬁ  cial gene network terminating and integrating 
into ANK1Advances and Applications in Bioinformatics and Chemistry 2008:1 97
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Genes Relation Network Score value
CASP14(NM_012114:CASP14)  1 A 0.2299
PSEN1(NM_007318:PSEN1)  1 A 0.2299
GRB14(NM_004490:GRB14)  1 A 0.2299
LIG1(NM_000234:LIG1)  1 A 0.2299
ALCAM(NM_001627:ALCAM)  1 A 0.2299
MAP3K8(NM_005204:MAP3K8)  1 A 0.2299
SHC3(NM_016848:SHC3)  1 A 0.2299
SURF1(NM_003172:SURF1) −1 B 0.2299
ANAPC4(NM_013367:ANAPC4)  1 B 0.2299
CENPE(NM_001813:CENPE)  1 B 0.2299
VHL(NM_000551:VHL) −1 B 0.2299
MAP2K3(NM_002756:MAP2K3) −1 B 0.2299
ST13(NM_003932:ST13)  1 B 0.2299
CDC25B(NM_004358:CDC25B)  1 B 0.2299
CDC45L(NM_003504:CDC45L)  1 B 0.2299
TP53(NM_000546:TP53)  1 B 0.2299
CCL2(NM_002982:CCL2)  1 B 0.2299
HSPB2(NM_001541:HSPB2)  1 B 0.2299
RUNX2(NM_004348:RUNX2)  1 B 0.2299
CSF2(NM_000758:CSF2) −1 B 0.2299
DUSP1(NM_004417:DUSP1)  1 B 0.2299
CDKN1A(NM_078467:CDKN1A) −1 B 0.2299
APOL3(NM_145642:APOL3)  1 B 0.2299
CDKN3(NM_005192:CDKN3)  1 B 0.2299
HSF1(NM_005526:HSF1) −1 B 0.2299
TNFRSF14(NM_003820:TNFRSF14) −1 B 0.2299
E2F5(NM_001951:E2F5)  1 B 0.2299
IL17(NM_002190:IL17)  1 B 0.2299
CCL2(NM_002982:CCL2)  1 C 0.2299
RUNX2(NM_004348:RUNX2) −1 C 0.2299
FCER2(NM_002002:FCER2)  1 C 0.2299
RIPK2(NM_003821:RIPK2)  1 C 0.2299
CDK5R1(NM_003885:CDK5R1)  1 C 0.2299
DNAJA1(NM_001539:DNAJA1) −1 C 0.2299
SMAD3(NM_005902:SMAD3) −1 C 0.2299
CTNNB1(NM_001904:CTNNB1) −1 C 0.2299
CCNA1(NM_003914:CCNA1)  1 C 0.2299
PPP5C(NM_006247:PPP5C) −1 C 0.2299
CDC2L5(NM_003718:CDC2L5) −1 C 0.2299
RAD51L3(NM_002878:RAD51L3) −1 C 0.2299
IRF2(NM_002199:IRF2)  1 C 0.2299
HSPB2(NM_001541:HSPB2) −1 C 0.2299
APOL3(NM_145642:APOL3) −1 C 0.2299
IL3RA(NM_002183:IL3RA)  1 C 0.2299
ARHE(NM_005168:ARHE) −1 C 0.2299
LZTS1(NM_021020:LZTS1) −1 C 0.2299
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Genes Relation Network Score value
PDGFC(NM_016205:PDGFC)  1 C 0.2299
MYC(NM_002467:MYC)  1 C 0.2299
CTL2(NM_020428:CTL2)  1 C 0.2299
TCEB3B(NM_016427:TCEB3B)  1 C 0.2299
E2F6(NM_001952:E2F6) −1 C 0.2299
TNFRSF19(NM_018647:TNFRSF19)  1 C 0.2299
IL11(NM_000641:IL11) −1 C 0.2299
HGFAC(NM_001528:HGFAC) −1 C 0.2299